pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

Iambic Therapeutics Inc

updated 3mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 1: 1
1Phase 1
Phase 1
IAM-1363
Bladder Cancer

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view Iambic Therapeutics Inc jobs →

News

  • Flagship blends three biotech startups to form Etcelera
    Etiome, Cellarity and Empress Therapeutics are being combined into one new AI-aided drugmaker claiming to possess the ability to better predict the way new medicines will fare in humans.
    biopharma_dive · 21d ago
  • Biotech notches 31 IPOs already this year, with 4 more joining queue
    The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…
    biospace · 28d ago
  • Iambic CEO on taking an AI drug company public
    Fresh off a $150 million IPO, Tom Miller spoke to BioPharma Dive about the roadshow process and how he sees AI’s role in drug development evolving.
    biopharma_dive · 1mo ago
  • City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
    City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.
    biospace · 1mo ago
  • Updated: Iambic rises after $150M IPO for AI-driven cancer pipeline
    Nvidia-backed Iambic Therapeutics rose on its first day of trading after pricing its $150 million initial public offering Wednesday night. The cancer-focused biotech's stock {$IAM} gained about 13%…
    endpoints · 1mo ago
  • Iambic goes public with $150M IPO to accelerate clinical development of oncology pipeline
    Iambic Therapeutics’ IPO came in dead on target, bringing in $150 million for the AI biotech to fuel the clinical development of its oncology pipeline.
    fiercebiotech · 1mo ago
  • Iambic, an AI drug discovery specialist, banks $150M in an IPO
    Part of a wave of young biotechs employing AI to accelerate research, the company claimed in regulatory filings that its approach has the potential to “disrupt legacy drug discovery paradigms.”
    biopharma_dive · 1mo ago
  • Parkinson’s cell therapy developer files to go public
    Aspen Neuroscience is looking to join the Nasdaq and raise more money to support its lead program, which aims to turn a patient's own cells into dopamine-producing neurons.
    biopharma_dive · 1mo ago
  • TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
    TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push…
    biospace · 1mo ago
  • Lilly-backed TRex rakes in $117M IPO, while hypertension biotech Retension reveals $45M listing
    Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals brought in $116.7 million and $45 million from their respective IPOs, continuing a bumper year for biotech listings.
    fiercebiotech · 1mo ago
view all news mentions →
identifiers
source
globaldata
top tags
Colorectal Cancer1NSCLC1Oncology1
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?